302 related articles for article (PubMed ID: 26420338)
21. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).
Takahama T; Sakai K; Takeda M; Azuma K; Hida T; Hirabayashi M; Oguri T; Tanaka H; Ebi N; Sawa T; Bessho A; Tachihara M; Akamatsu H; Bandoh S; Himeji D; Ohira T; Shimokawa M; Nakanishi Y; Nakagawa K; Nishio K
Oncotarget; 2016 Sep; 7(36):58492-58499. PubMed ID: 27542267
[TBL] [Abstract][Full Text] [Related]
22. The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer.
Ross K; Pailler E; Faugeroux V; Taylor M; Oulhen M; Auger N; Planchard D; Soria JC; Lindsay CR; Besse B; Vielh P; Farace F
Expert Rev Mol Diagn; 2015; 15(12):1605-29. PubMed ID: 26564313
[TBL] [Abstract][Full Text] [Related]
23. Circulating tumor cells in patients with lung cancer: developments and applications for precision medicine.
Tong B; Wang M
Future Oncol; 2019 Jul; 15(21):2531-2542. PubMed ID: 31339062
[TBL] [Abstract][Full Text] [Related]
24. Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer.
Imamura F; Uchida J; Kukita Y; Kumagai T; Nishino K; Inoue T; Kimura M; Oba S; Kato K
Lung Cancer; 2016 Apr; 94():68-73. PubMed ID: 26973209
[TBL] [Abstract][Full Text] [Related]
25. Determination of EGFR mutations in single cells microdissected from enriched lung tumor cells in peripheral blood.
Ran R; Li L; Wang M; Wang S; Zheng Z; Lin PP
Anal Bioanal Chem; 2013 Sep; 405(23):7377-82. PubMed ID: 23828210
[TBL] [Abstract][Full Text] [Related]
26. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
[TBL] [Abstract][Full Text] [Related]
27. Impact of Epidermal Growth Factor Receptor Mutation on Clinical Outcomes of Nintedanib Plus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer from the Korean Named Patient Program.
Hong SH; An HJ; Kim K; Lee SS; Lee YG; Yuh YJ; Park IC; Chae YS; Jang TW; Kang JH
Oncology; 2019; 96(1):51-58. PubMed ID: 30368503
[TBL] [Abstract][Full Text] [Related]
28. Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis.
Sands J; Li Q; Hornberger J
Lung Cancer; 2017 Aug; 110():19-25. PubMed ID: 28676213
[TBL] [Abstract][Full Text] [Related]
29. Droplet digital PCR-based EGFR mutation detection with an internal quality control index to determine the quality of DNA.
Kim SS; Choi HJ; Kim JJ; Kim MS; Lee IS; Byun B; Jia L; Oh MR; Moon Y; Park S; Choi JS; Chae SW; Nam BH; Kim JS; Kim J; Min BS; Lee JS; Won JK; Cho SY; Choi YL; Shin YK
Sci Rep; 2018 Jan; 8(1):543. PubMed ID: 29323170
[TBL] [Abstract][Full Text] [Related]
30. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
Alix-Panabières C; Pantel K
Cancer Discov; 2016 May; 6(5):479-91. PubMed ID: 26969689
[TBL] [Abstract][Full Text] [Related]
31. Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.
Levy B; Hu ZI; Cordova KN; Close S; Lee K; Becker D
Oncologist; 2016 Sep; 21(9):1121-30. PubMed ID: 27388233
[TBL] [Abstract][Full Text] [Related]
32. Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series.
Tchekmedyian N; Mudad R; Blanco FF; Raymond VM; Garst J; Erlander MG; Haura E; Berz D
Lung Cancer; 2017 Jun; 108():22-28. PubMed ID: 28625639
[TBL] [Abstract][Full Text] [Related]
33. EGFR mutations in lung cancer: from tissue testing to liquid biopsy.
Fenizia F; De Luca A; Pasquale R; Sacco A; Forgione L; Lambiase M; Iannaccone A; Chicchinelli N; Franco R; Rossi A; Morabito A; Rocco G; Piccirillo MC; Normanno N
Future Oncol; 2015; 11(11):1611-23. PubMed ID: 26043215
[TBL] [Abstract][Full Text] [Related]
34. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
[TBL] [Abstract][Full Text] [Related]
35. Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory Practice: A Cross-Platform Comparison of Three Different Molecular Methods for Mutation Detection.
Bartels S; Persing S; Hasemeier B; Schipper E; Kreipe H; Lehmann U
J Mol Diagn; 2017 Sep; 19(5):722-732. PubMed ID: 28723342
[TBL] [Abstract][Full Text] [Related]
36. Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs.
Chen S; Zhao J; Cui L; Liu Y
Clin Transl Oncol; 2017 Mar; 19(3):332-340. PubMed ID: 27468867
[TBL] [Abstract][Full Text] [Related]
37. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas.
Taniguchi K; Uchida J; Nishino K; Kumagai T; Okuyama T; Okami J; Higashiyama M; Kodama K; Imamura F; Kato K
Clin Cancer Res; 2011 Dec; 17(24):7808-15. PubMed ID: 21976538
[TBL] [Abstract][Full Text] [Related]
38. Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation.
Vallée A; Audigier-Valette C; Herbreteau G; Merrien J; Tessonnier L; Théoleyre S; Denis MG
Lung Cancer; 2016 Jan; 91():73-4. PubMed ID: 26612314
[No Abstract] [Full Text] [Related]
39. A Novel Technique to Detect EGFR Mutations in Lung Cancer.
Liu Y; Lei T; Liu Z; Kuang Y; Lyu J; Wang Q
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27223277
[TBL] [Abstract][Full Text] [Related]
40. Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer.
Akca H; Demiray A; Yaren A; Bir F; Koseler A; Iwakawa R; Bagci G; Yokota J
Cancer Genet; 2013 Mar; 206(3):73-80. PubMed ID: 23491080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
